Summary with embedded links to primary sources.
“Ivermectin is an anti-parasite medicine whose discovery won the Nobel Prize in 2015 for its impacts in ridding large parts of the globe of parasitic diseases via distribution of over 3.7 billion doses within public health campaigns since 1987.
Since 2012, numerous in-vitro studies began to report highly potent anti-viral effects against a diverse array of viruses, including SARS-CoV-2 along with numerous anti-inflammatory and immuno-modulating effects…
Currently, as of September 19, 2021, the totality of the evidence is as follows:
- IN-VITRO (BASIC SCIENCE): ivermectin has been shown to inhibit the replication of many viruses, including West-Nile, Zika, Dengue, Influenza, and most recently SARS-CoV-2
- IN-VIVO: ivermectin diminishes viral load and protects against organ damage in animal models of SARS-CoV-2 infection and has multiple, potent anti-inflammatory and immune-modulating properties ...
- CLINICAL OBSERVATIONS/EXPERIENCE: numerous cases series, most notably one published from the Dominican Republic in June 2020 where over 3,000 consecutive patients presented to the ER, were treated with ivermectin, and only 16 were hospitalized and only 1 died. Also, innumerable doctors from multiple countries around the world report observing consistent clinical responses in treated patients with few treatment failures.
- OBSERVATIONAL CONTROLLED TRIALS (OCT): As of August 8, 2021, the results from 31 OCT’s including over 6,800 patients find that treatment with ivermectin reduces time to recovery, rates of hospitalization, and mortality, the latter finding best reported in the sophisticated propensity-matched study of Rajter et al. published in the major medical journal Chest.
- META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS (RCT): 27 RCT’s including over 3,400 patients have been completed. Meta-analyses find that ivermectin reduces time to viral clearance, hastens recovery, and reduces mortality.
- OBSERVATIONAL AND RANDOMIZED TRIALS IN THE PREVENTION OF COVID-19: A series of 13 RCT’s and OCT’s consistently find that single or repeated ivermectin use strongly reduces the risk of contracting COVID-19, with an average level of protection of 86% with higher levels of protection found amongst the trials with more frequent dosing.
Conclusion: Based on the totality of the existing evidence above, the FLCCC strongly recommends ivermectin be used in both the prevention and treatment of all phases of COVID-19 in both vaccinated and unvaccinated populations.”